AYTU BIOPHARMA, INC business relationships
Companies named in AYTU BIOPHARMA, INC’s 10-K filed 2026-09-22, and public companies whose annual reports name AYTU BIOPHARMA, INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 12 / 100 Top 2% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in AYTU BIOPHARMA, INC’s annual report 5
“...October 17, 2017, we entered into a Settlement Agreement and a Licensing Agreement with Actavis (which is now owned by Teva Pharmaceutical Industries Limited), pursuant to which we granted Actavis the right to manufacture and market its now approved generic version of Adzenys under the ANDA beginni...” SEC filing
“Through a supply and distribution agreement with Tris Pharma, Inc. ("Tris"), we own exclusive rights to commercialize Karbinal in the United States through August 2033, unless the agreement is terminated earlier pursuant to the termination provisions in the agreement.” SEC filing
“Settlement and Termination of License Agreement between the registrant and TRIS Pharma, Inc., dated May 12, 2022.” SEC filing
“In September 2024, we entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd ("Lupin"), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to commercialize Adzenys and Cotempla in Canada.” SEC filing
“| Termination of License and Distribution Agreement between Aytu BioPharma, Inc. and Lannett Company, Inc. |” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.